Shu-Hong Li

932 citations
9 papers · 768 indexed · h-index 8
Topics
Cholangiocarcinoma and Gallbladder Cancer Studies (4 papers)Hepatocellular Carcinoma Treatment and Prognosis (3 papers)Liver Disease Diagnosis and Treatment (2 papers)

In The Last Decade

Shu-Hong Li

9 papers receiving 756 citations

Peers

Shu-Hong Li
Comparison fields: 5 of 75
  • Molecular Biology 313
  • Surgery 204
  • Epidemiology 145
  • Cardiology and Cardiovascular Medicine 139
  • Biomedical Engineering 122
Replace I‐Ping Chiang with:
I‐Ping Chiang Taiwan
Teiji Oda Japan
Michio Ogawa Japan
Miriam Boersema Netherlands
Joon Ho Lee South Korea
Ahu Sarbay Kemık Türkiye
Wen Tian United States
Saleh Yazdani Netherlands
Koralia Paschalaki United Kingdom
Rafia S. Al‐Lamki United Kingdom
Shu-Hong Li relative to I‐Ping Chiang Taiwan I‐Ping Chiang's profile →
Citations per field
00.5×6.4×
I‐Ping Chiang · 1×
Citations per year

Countries citing papers authored by Shu-Hong Li

Since Specialization
Citations

This map shows the geographic impact of Shu-Hong Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shu-Hong Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shu-Hong Li more than expected).

Fields of papers citing papers by Shu-Hong Li

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shu-Hong Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shu-Hong Li. The network helps show where Shu-Hong Li may publish in the future.

Co-authorship network of co-authors of Shu-Hong Li

This figure shows the co-authorship network connecting the top 25 collaborators of Shu-Hong Li. A scholar is included among the top collaborators of Shu-Hong Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shu-Hong Li. Shu-Hong Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
#WorkIndexed citations
1 35
2 8
3 24
4 43
5 29
6 5
7 91
8 100
9 433

About Shu-Hong Li

Shu-Hong Li is a scholar working on Hepatology, Biochemistry and Biomaterials, having authored 9 papers that have together received 768 indexed citations. Recurring topics across this work include Cholangiocarcinoma and Gallbladder Cancer Studies (4 papers), Hepatocellular Carcinoma Treatment and Prognosis (3 papers) and Liver Disease Diagnosis and Treatment (2 papers). The work is most often cited by research in Hepatology (73 citations), Cancer Research (102 citations) and Cardiology and Cardiovascular Medicine (139 citations). Shu-Hong Li has collaborated with scholars based in China, Canada and United Kingdom. Frequent co-authors include Richard D. Weisel, Chao‐Hung Wang, Donald A.G. Mickle, Liana Zucco, Paul E. Szmitko, Mitesh Badiwala, Subodh Verma, Michael A. Kuliszewski, Michael J.B. Kutryk and Paul W.M. Fedak. Their work appears in journals such as Circulation, International Journal of Molecular Sciences and European Heart Journal.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026